CD22 and neoplasm: In the SW900 model, doses as low as 0.1 mg/kg of anti-Ly6Ev2-CBI enabled modest tumor regression, and the 0.2 mg/kg dose was substantially separated from the untargeted control (anti-CD22) (Figure 6b).